Literature DB >> 16870770

Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Feng Wang1, Craig Cassidy, James C Sacchettini.   

Abstract

beta-Lactam antibiotics are extremely effective in disrupting the synthesis of the bacterial cell wall in both gram-positive and gram-negative bacteria. However, they are ineffective against Mycobacterium tuberculosis, due to the production of a beta-lactamase enzyme encoded on the chromosome of M. tuberculosis that degrades these antibiotics. Indeed, recent studies have demonstrated that deletion of the blaC gene, the only gene encoding a beta-lactamase in M. tuberculosis, or inhibition of the encoded enzyme resulted in significantly increased sensitivity to beta-lactam antibiotics. In this paper we present a biochemical and structural characterization of M. tuberculosis BlaC. Recombinant BlaC shows a broad range of specificity with almost equal penicillinase and cepholothinase activity. While clavulanate is a mechanism-based inhibitor to class A beta-lactamase with high potency (typically K(i) < 0.1 microM), it is a relatively poor inhibitor of the M. tuberculosis BlaC (K(i) = 2.4 microM). The crystal structure of the enzyme, determined at a resolution of 1.7 A, shows that the overall fold of the M. tuberculosis enzyme is similar to other class A beta-lactamases. There are, however, several distinct features of the active site, such as the amino acid substitutions N132G, R164A, R244A, and R276E, that explain the broad specificity of the enzyme, relatively low penicillinase activity, and resistance to clavulanate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870770      PMCID: PMC1538687          DOI: 10.1128/AAC.00320-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  52 in total

1.  Porins in the cell wall of mycobacteria.

Authors:  J Trias; V Jarlier; R Benz
Journal:  Science       Date:  1992-11-27       Impact factor: 47.728

Review 2.  Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics.

Authors:  A A Medeiros
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

3.  Bacterial resistance to beta-lactam antibiotics: crystal structure of beta-lactamase from Staphylococcus aureus PC1 at 2.5 A resolution.

Authors:  O Herzberg; J Moult
Journal:  Science       Date:  1987-05-08       Impact factor: 47.728

4.  Crystal structures of the Bacillus licheniformis BS3 class A beta-lactamase and of the acyl-enzyme adduct formed with cefoxitin.

Authors:  Eveline Fonzé; Marc Vanhove; Georges Dive; Eric Sauvage; Jean-Marie Frère; Paulette Charlier
Journal:  Biochemistry       Date:  2002-02-12       Impact factor: 3.162

5.  Ultrahigh resolution structure of a class A beta-lactamase: on the mechanism and specificity of the extended-spectrum SHV-2 enzyme.

Authors:  Michiyoshi Nukaga; Kayoko Mayama; Andrea M Hujer; Robert A Bonomo; James R Knox
Journal:  J Mol Biol       Date:  2003-04-18       Impact factor: 5.469

Review 6.  Inactivation of antibiotics and the dissemination of resistance genes.

Authors:  J Davies
Journal:  Science       Date:  1994-04-15       Impact factor: 47.728

7.  Ab initio QM/MM study of class A beta-lactamase acylation: dual participation of Glu166 and Lys73 in a concerted base promotion of Ser70.

Authors:  Samy O Meroueh; Jed F Fisher; H Bernhard Schlegel; Shahriar Mobashery
Journal:  J Am Chem Soc       Date:  2005-11-09       Impact factor: 15.419

8.  Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors:  R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

9.  Acyl-intermediate structures of the extended-spectrum class A beta-lactamase, Toho-1, in complex with cefotaxime, cephalothin, and benzylpenicillin.

Authors:  Tatsuro Shimamura; Akiko Ibuka; Shinya Fushinobu; Takayoshi Wakagi; Masaji Ishiguro; Yoshikazu Ishii; Hiroshi Matsuzawa
Journal:  J Biol Chem       Date:  2002-09-08       Impact factor: 5.157

10.  The crystal structure of the beta-lactamase of Streptomyces albus G at 0.3 nm resolution.

Authors:  O Dideberg; P Charlier; J P Wéry; P Dehottay; J Dusart; T Erpicum; J M Frère; J M Ghuysen
Journal:  Biochem J       Date:  1987-08-01       Impact factor: 3.857

View more
  60 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

2.  Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo.

Authors:  Kathleen England; Helena I M Boshoff; Kriti Arora; Danielle Weiner; Emmanuel Dayao; Daniel Schimel; Laura E Via; Clifton E Barry
Journal:  Antimicrob Agents Chemother       Date:  2012-03-26       Impact factor: 5.191

3.  Imaging tuberculosis with endogenous beta-lactamase reporter enzyme fluorescence in live mice.

Authors:  Ying Kong; Hequan Yao; Hongjun Ren; Selvakumar Subbian; Suat L G Cirillo; James C Sacchettini; Jianghong Rao; Jeffrey D Cirillo
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-21       Impact factor: 11.205

Review 4.  A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.

Authors:  Alain Philippon; Patrick Slama; Paul Dény; Roger Labia
Journal:  Clin Microbiol Rev       Date:  2016-01       Impact factor: 26.132

5.  Saturation mutagenesis of Asn152 reveals a substrate selectivity switch in P99 cephalosporinase.

Authors:  Scott T Lefurgy; René M de Jong; Virginia W Cornish
Journal:  Protein Sci       Date:  2007-12       Impact factor: 6.725

Review 6.  Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors:  Liem Nguyen
Journal:  Arch Toxicol       Date:  2016-05-09       Impact factor: 5.153

Review 7.  World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential?

Authors:  Kelly E Dooley; Ekwaro A Obuku; Nadza Durakovic; Vera Belitsky; Carole Mitnick; Eric L Nuermberger
Journal:  J Infect Dis       Date:  2012-07-17       Impact factor: 5.226

8.  High tolerance to simultaneous active-site mutations in TEM-1 beta-lactamase: Distinct mutational paths provide more generalized beta-lactam recognition.

Authors:  Pierre-Yves De Wals; Nicolas Doucet; Joelle N Pelletier
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

9.  Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.

Authors:  Philippe Egesborg; Hélène Carlettini; Jordan P Volpato; Nicolas Doucet
Journal:  Protein Sci       Date:  2014-12-30       Impact factor: 6.725

10.  In vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems.

Authors:  Mathilde Cordillot; Vincent Dubée; Sébastien Triboulet; Lionel Dubost; Arul Marie; Jean-Emmanuel Hugonnet; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.